1083P KEYMAKER 02B: A randomized trial of pembrolizumab (pembro) alone or with investigational agents as first-line treatment for advanced melanoma. - Dummer, R.; Shapira, R.; Pigozzo, J.; Ascierto, P.A.; Gaudy Marqueste, C.; Portnoy, D.; Del Vecchio, M.; Bar-Sela, G.; Cohen, J.E.; Di Giacomo, A.M.; Ribas, A.; Dutriaux, C.; et al. (Annals of Oncology, 2024)